| Bioactivity | NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation[1]. | ||||||||||||
| Invitro | NHWD-870 (0.01-10000 nM) inhibits melanoma cells (A375) with an IC50 of 2.46 nM[1].NHWD-870 (0-10000 nM; 5 dys) suppressed cell growth[1].NHWD-870 (0-50 nM; 24 hours) inhibits BRD4 phosphorylation and c-MYC expression[1].NHWD-870 exhibits mild inhibition of hERG channel (IC50 = 5.4 µM)[1].NHWD-870 shows robust activities inducing apoptosis and suppressing cell proliferation[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | NHWD-870 | ||||||||||||
| CAS | 2115742-03-3 | ||||||||||||
| Formula | C29H29N7O | ||||||||||||
| Molar Mass | 491.59 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
NHWD-870
CAS: 2115742-03-3 F: C29H29N7O W: 491.59
NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2,
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.